Clinical Study

Raphael Aml003 Phase III Multicenter Open-Label Randomized Trial To Evaluate Efficacy And Safety Of Cpi-613 In Combination With High Dose Cytarabine And Mitoxantrone (Cham) Compared To High Dose Cytarabine And Mitoxantrone (Ham) In Older Patients (≥

Posted Date: Jun 10, 2019

  • Investigator: Zartash Gul
  • Specialties: Cancer, Leukemia, Oncology
  • Type of Study: Drug

To determine efficacy of Cytarabine and Mitoxantrone versus Cytarabine and Mitoxantrone in combination with CPI-613 in terms of CR in older patients with acute myeloid leukemia.


Adults Over 60 Years Of Age, Expected Survival Of >3 Months, No Previous Cytotoxic Chemotherapy Treatment, No Active Uncontrolled Bleeding, No History Of Other Malignancy In The Past 5 Years



For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.